Clinical trial· 2006
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
The Journal of clinical endocrinology and metabolism
Back to all molecules
Human researchNot FDA-approved
CJC-1295
Long-acting GHRH analog
Also indexed as: CJC-1295 with DAC · DAC-GRF
What this evidence does not tell us
The cited trial studies the long-acting DAC form and hormone responses, not proof of improved recovery or anti-aging benefit. Modified GRF (1–29) without DAC is not interchangeable.
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
9 glossary terms used in this profile
Terms on this page
Unfamiliar word? Open this panel for simple explanations, right here.
9 glossary terms used in this profile
Select a word to see its meaning. You can keep more than one definition open.
Definitions explain the words—not whether a molecule works or is safe. Research education only, not medical advice.
Overview
CJC-1295 is a synthetic analog of growth hormone-releasing hormone. The published human research highlighted here concerns its long-acting DAC form, not all products marketed under similar names.
Mechanism of action
GHRH / GH–IGF-1
A synthetic growth hormone-releasing hormone analog. The long-acting DAC form binds albumin to prolong exposure and stimulates the GHRH receptor upstream of GH/IGF-1.
A biological pathway describes a proposed or observed interaction—not necessarily a demonstrated health outcome.
Decode the terminology in our glossaryScientific evidence
How strong is the evidence?
Human evidence is still developing
- Limited evidence
- Early research
- Human researchCurrent category
- Human outcomes
Studies in people exist, but the findings may be small, narrow, mixed or still need confirmation. A hormone or cell marker is not necessarily a health benefit.
For this research: The cited trial studies the long-acting DAC form and hormone responses, not proof of improved recovery or anti-aging benefit. Modified GRF (1–29) without DAC is not interchangeable.
An editorial guide—not a validated score, a percentage, a safety rating or an approval badge. Regulatory status is separate. More research does not mean fewer risks.
Cell studies
Mechanistic laboratory evidence is not separately assessed in this selected-source summary; see references and their study types.
Animal experiments
Animal evidence is not separately assessed here. Findings in animals must not be interpreted as demonstrated human benefit.
Human observational studies
Associations, biomarker studies and anecdotes cannot establish treatment causality; no observational result is used here to infer clinical effectiveness.
Human clinical trials
Small randomized human pharmacology studies measured GH/IGF-1 and tolerability; clinical recovery was not established.
Regulatory evidence
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Potential research applications
GH and IGF-1 responses and pharmacokinetics in controlled research.
These describe scientific questions, not prescribing recommendations. A research grouping does not establish combination safety or clinical effectiveness.
Explore research by health goalSafety considerations
Potential glucose intolerance, fluid retention and endocrine effects; FDA reports increased heart rate and systemic vasodilatory reactions.
This is not an exhaustive safety or contraindication list. An absence of reported harm is not proof of safety. Pregnancy, breastfeeding, cancer history, endocrine disease and concurrent medicines can materially change risk. Unregulated preparations add identity, contamination and sterility risks.
Read FDA’s compounding safety informationRegulatory status · United States
Not FDA-approved
No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Regulatory status and evidence strength are different. A nomination for compounding, a clinical-trial registration or a “research use only” label is not approval. International rules vary; consult the current regulator and product label.
Selected literature & source transparency
Matched bibliographic records confirm a publication’s identity, not the validity of every claim. Selected sources are not a systematic literature review.
Continue your own source search
These open search results, not additional verified citations. Trial registration is not evidence that a treatment works.
Three questions worth bringing to your clinician
- Which human outcomes—not just biomarkers—support this claim?
- What established options address my actual health concern?
- What do my medical history and current medicines change about the risks?
Beyond the library
Turn better questions into a thoughtful conversation.
Explore our broader health optimization approach. A library entry does not mean a molecule is offered, prescribed, or appropriate for you.
Request an Optimization Consultation
Continue to our existing activation & intake page.